Hosted on MSN12d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show ...
Is Novo Nordisk A/S (NVO) The Best Beaten Down Stock to Buy According to Analysts?
We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts. In this article, we are going to ...
Novo Nordisk: Not As Bullish As Many
Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...
NBC 10 Philadelphia12d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...